Overview Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers Status: COMPLETED Trial end date: 2023-08-06 Target enrollment: Participant gender: Summary This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of SPL84 single ascending doses (SAD) in healthy volunteers (HV)Phase: PHASE1 Details Lead Sponsor: SpliSense Ltd.